Stockscreener 앱 받기
55.11
0.86%
0.49
전일 마감가:
$54.62
열려 있는:
$55
하루 거래량:
92,285
Relative Volume:
0.17
시가총액:
$3.10B
수익:
$32.87M
순이익/손실:
$674.31M
주가수익비율:
-13.95
EPS:
-3.95
순현금흐름:
$-330.11M
1주 성능:
-0.56%
1개월 성능:
+20.66%
6개월 성능:
+62.61%
1년 성능:
+151.90%
1일 변동 폭
$53.93
$55.29
1주일 범위
$52.09
$55.67
52주 변동 폭
$20.96
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
명칭
Agios Pharmaceuticals Inc
전화
617-649-8600
주소
88 SIDNEY STREET, CAMBRIDGE, MA
AGIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| AGIO | 55.11 | 3.10B | 32.87M | 674.31M | -330.11M | -3.95 |
| VRTX | 446.83 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.22 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.15 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.71 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 104.52 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 개시 | Piper Sandler | Overweight |
| 2022-11-17 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-03-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-02-15 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 개시 | Leerink Partners | Mkt Perform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-04-11 | 재확인 | Credit Suisse | Outperform |
| 2018-02-15 | 재확인 | Needham | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-10 | 재확인 | Needham | Buy |
| 2017-08-08 | 재확인 | SunTrust | Buy |
| 2017-08-02 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-01-17 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 개시 | Needham | Buy |
| 2016-06-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 재확인 | SunTrust | Buy |
모두보기
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
Beta-thalassemia Market is Predicted to Exhibit Remarkable - openPR
(AGIO) Pivots Trading Plans and Risk Controls - Stock Traders Daily
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - GlobeNewswire Inc.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Sees Significant Growth in Short Interest - MarketBeat
Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $52.33 - MarketBeat
ARMISTICE CAPITAL, LLC Expands Portfolio with Agios Pharmaceuticals Inc - GuruFocus.com
Agios Pharmaceuticals director sells shares worth $1.12 million By Investing.com - Investing.com Canada
Agios Pharmaceuticals director sells shares worth $1.12 million - Investing.com India
Agios Pharmaceuticals chief legal officer sells $1.14 million in stock - Investing.com India
Agios Pharmaceuticals chief legal officer sells $1.14 million in stock By Investing.com - Investing.com UK
StockNews.com Upgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Hold - MarketBeat
Agios stock soars to 52-week high, reaching $53.28 By Investing.com - Investing.com Canada
Agios stock soars to 52-week high, reaching $53.28 - Investing.com
Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News - Yahoo Finance
Agios Pharmaceuticals' SWOT analysis: promising pipeline, cash boost fuel stock outlook - Investing.com India
Mirae Asset Global Investments Co. Ltd. Acquires 363 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition - The Manila Times
Agios to Unveil Critical Phase 3 Data for Blood Disorder Drugs at ASH 2024 | AGIO Stock News - StockTitan
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Rating Lowered to “Sell” at StockNews.com - Defense World
Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga
Agios Pharmaceuticals (NASDAQ:AGIO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat
AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down - Yahoo Finance
Agios Pharmaceuticals (NASDAQ:AGIO) Given New $53.00 Price Target at Scotiabank - MarketBeat
Agios shares hold Strong Buy rating, $51 target from Raymond James - Investing.com Australia
Earnings call: Agios Pharmaceuticals reports Q3 2024 financials, plans launches - Investing.com Australia
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2024 Earnings Call Transcript - Insider Monkey
Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings Call Highlights: Strong Cash Position and Strategic Advancements - GuruFocus.com
Agios Pharmaceuticals: Q3 Earnings Snapshot - The Advocate
Agios Pharmaceuticals Reports Robust Q3 2024 Results - TipRanks
Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates - MSN
Agios Pharmaceuticals Inc (AGIO) Q3 2024 Earnings: EPS Surpasses Estimates, Revenue at $9.0 Million - GuruFocus.com
Agios Reports Business Highlights and Third Quarter 2024 Financial Results - The Manila Times
Earnings Preview: Agios Pharmaceuticals - Benzinga
Leerink Partnrs Issues Optimistic Estimate for AGIO Earnings - MarketBeat
Analysts Are Optimistic We'll See A Profit From Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Simply Wall St
Equities Analysts Set Expectations for AGIO Q3 Earnings - MarketBeat
Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts By Investing.com - Investing.com Australia
Agios Pharmaceuticals (AGIO) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Agios Pharmaceuticals' SWOT analysis: stock outlook amid SCD market shifts - Investing.com India
Servier vorasidenib PDUFA near, Agios wins in thalassemia - BioWorld Online
Agios completes enrollment for sickle cell disease trial By Investing.com - Investing.com Canada
Agios completes enrollment for sickle cell disease trial - Investing.com
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease - The Manila Times
Agios Pharmaceuticals Inc (AGIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Agios Pharmaceuticals Inc 주식 (AGIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ballal Rahul D. | Director |
Nov 07 '24 |
Option Exercise |
25.99 |
10,000 |
259,900 |
17,992 |
| Ballal Rahul D. | Director |
Nov 08 '24 |
Option Exercise |
25.99 |
10,000 |
259,900 |
17,992 |
| Ballal Rahul D. | Director |
Nov 08 '24 |
Sale |
58.19 |
10,000 |
581,911 |
7,992 |
| Ballal Rahul D. | Director |
Nov 07 '24 |
Sale |
53.52 |
10,000 |
535,236 |
7,992 |
| Burns James William | Chief Legal Officer |
Nov 07 '24 |
Sale |
52.21 |
21,752 |
1,135,775 |
15,700 |
0.42%
0.16%
자본화:
|
볼륨(24시간):